title: Prophylaxis of infectious complications with colony-stimulating factors in adult cancer patients undergoing chemotherapy-evidence-based guidelines from the Infectious Diseases Working Party AGIHO of the German Society for Haematology and Medical Oncology (DGHO).
abstract: BACKGROUND
  Current evidence on myelopoietic growth factors is difficult to overview for the practicing haematologist/oncologist. International guidelines are sometimes conflicting, exclude certain patient groups, or cannot directly be applied to the German health system. This guideline by the Infectious Diseases Working Party (AGIHO) of the German Society of Haematology and Medical Oncology (DGHO) gives evidence-based recommendations for the use of G-CSF, pegylated G-CSF, and biosimilars to prevent infectious complications in cancer patients undergoing chemotherapy, including those with haematological malignancies.
  
  
  METHODS
  We systematically searched and evaluated current evidence. An expert panel discussed the results and recommendations. We then compared our recommendations to current international guidelines.
  
  
  RESULTS
  We summarised the data from eligible studies in evidence tables, developed recommendations for different entities and risk groups.
  
  
  CONCLUSIONS
  Comprehensive literature search and expert panel consensus confirmed many key recommendations given by international guidelines. Evidence for growth factors during acute myeloid leukaemia induction chemotherapy and pegfilgrastim use in haematological malignancies was rated lower compared with other guidelines.
authors.affiliation: 1st Department of Internal Medicine, University Hospital of Cologne, Cologne.
authors.forename: J J
authors.initials: JJ
authors.lastname: Vehreschild
authors.affiliation: Onkologikum Frankfurt am Museumsufer, Frankfurt a.M.
authors.forename: A
authors.initials: A
authors.lastname: Böhme
authors.affiliation: 1st Department of Internal Medicine, University Hospital of Cologne, Cologne; Clinical Trials Centre Cologne (ZKS Köln, BMBF 01KN1106); Centre for Integrated Oncology CIO KölnBonn, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Cologne. Electronic address: oliver.cornely@uk-koeln.de.
authors.forename: O A
authors.initials: OA
authors.lastname: Cornely
authors.affiliation: Clinic for Haematology and Oncology, Klinikum Magdeburg gGmbH.
authors.forename: C
authors.initials: C
authors.lastname: Kahl
authors.affiliation: Haematology-Oncology and Palliative Care, Hospital Neuperlach and Hospital Harlaching, Munich.
authors.forename: M
authors.initials: M
authors.lastname: Karthaus
authors.affiliation: 1st Department of Internal Medicine, University Hospital of Cologne, Cologne.
authors.forename: K-A
authors.initials: KA
authors.lastname: Kreuzer
authors.affiliation: Department of Haematology, Oncology and Palliative Care, Klinikum Ernst von Bergmann, Potsdam.
authors.forename: G
authors.initials: G
authors.lastname: Maschmeyer
authors.affiliation: Medizinische Klinik II, University Hospital Frankfurt a.M., Frankfurt a.M.
authors.forename: S
authors.initials: S
authors.lastname: Mousset
authors.affiliation: Clinical Trials Centre Cologne (ZKS Köln, BMBF 01KN1106).
authors.forename: V
authors.initials: V
authors.lastname: Ossendorf
authors.affiliation: Campus Benjamin Franklin; Medical Clinic for Haematology and Oncology, University Hospital Charité, Berlin, Germany.
authors.forename: O
authors.initials: O
authors.lastname: Penack
authors.affiliation: 1st Department of Internal Medicine, University Hospital of Cologne, Cologne.
authors.forename: M J G T
authors.initials: MJGT
authors.lastname: Vehreschild
authors.affiliation: Institute for Social and Preventive Medicine, University of Bern, Bern, Switzerland.
authors.forename: J
authors.initials: J
authors.lastname: Bohlius
mesh_terms: D000328:Adult; D019072:Antibiotic Prophylaxis / Q000379:methods*; D003140:Communicable Disease Control / Q000379:methods*; D003141:Communicable Diseases / Q000188:drug therapy; D019317:Evidence-Based Medicine; D064147:Febrile Neutropenia / Q000188:drug therapy / Q000517:prevention & control; D000069585:Filgrastim; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use*; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000382:microbiology; D011092:Polyethylene Glycols / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D011994:Recombinant Proteins; C486981:pegylated granulocyte colony-stimulating factor, human; D016179:Granulocyte Colony-Stimulating Factor; C455861:pegfilgrastim; D011092:Polyethylene Glycols; D000069585:Filgrastim
keywords: G-CSF; cancer; evidence-based guideline; febrile neutropenia; infection; supportive care